Biotech · Private company · Cambridge, MA, US

Nuvalent, Inc.

SEC CIK 0001861560

Track this companyFree. Adds Nuvalent, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials54 recruiting or active

Pipeline programs9From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

Pipeline9

AlectinibPhase 3 · Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
Neladalkib (NVL-655)Phase 3 · Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
ItraconazolePhase 2 · Locally Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
MidazolamPhase 2 · Locally Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
Neladalkib (NVL-655)Phase 2 · Locally Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
RepaglinidePhase 2 · Locally Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
Zidesamtinib (NVL-520)Phase 2 · Locally Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
NVL-330Phase 1 · Locally Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
NVL-655Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLCPHASE3 · RECRUITING · started Jul 17, 2025ClinicalTrials.gov NCT06765109 · fetched Nov 12, 2026
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)PHASE1 · RECRUITING · started Jul 18, 2024ClinicalTrials.gov NCT06521554 · fetched Nov 12, 2026
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)PHASE1_PHASE2 · RECRUITING · started Jun 9, 2022ClinicalTrials.gov NCT05384626 · fetched Nov 12, 2026
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)PHASE1_PHASE2 · RECRUITING · started Jan 4, 2022ClinicalTrials.gov NCT05118789 · fetched Nov 12, 2026
Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid TumorsAVAILABLEClinicalTrials.gov NCT06834074 · fetched Nov 12, 2026